References

1. Szot P, Weinshenker D, Rho JM, Storey TW, Schwartzkroin PA. Norepinephrine is required for the anticonvulsant effect of the ketogenic diet. Dev Brain Res 2001;129:211-214.

2. Hökfelt T, Broberger C, Diez M, Xu ZQ, Shi T, Kopp J, Zhang X, Holmberg K, Landry M, Koistinaho J. Galanin and NPY, two peptides with multiple putative roles in the nervous system. Horm Metab Res 1999;31:330-334.

3. Wynick D, Bacon A. Targeted disruption of galanin: new insights from knock-out studies. Neuropep-tides 2002;36:132-144.

4. Gundlach AL. Galanin/GALP and galanin receptors: role in central control of feeding, body weight/obesity and reproduction? Eur J Pharmacol 2002;440:255-268.

5. Kalra SP, Horvath TL. Neuroendocrine interactions between galanin, opioids, and neuropeptide Y in the control of reproduction and appetite. Ann N Y Acad Sci 1998;863:236-240.

6. Gehlert DR. Role of hypothalamic neuropeptide Y in feeding and obesity. Neuropeptides 1999;33:329-338.

7. Allen YS, Adrian TE, Allen JM, Tatemoto K, Crow TJ, Bloom SR, Polak JM. Neuropeptide Y distribution in the rat brain. Science 1983;221:877-879.

8. Chronwall BM, DiMaggio DA, Massari VJ, Pickel VM, Ruggiero DA, O'Donohue TL. The anatomy of neuropeptide-Y-containing neurons in rat brain. Neuroscience 1985;15:1159-1181.

9. de Quidt ME, Emson PC. Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system: II. Immunohistochemical analysis. Neuroscience 1986;18:545-618.

10. Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T. XVI International Union of Pharmacology Recommendations for the Nomenclature of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Receptors. Pharmacol Rev 1998;50:143-150.

11. Rahmouni K, Haynes WG. Leptin signaling pathways in the central nervous system: interactions between neuropeptide Y and melanocortins. BioEssays 2001;23:1095-1099.

12. Williams G, Bing C, Cai XJ, Harrold JA, King PJ, Liu XH. The hypothalamus and the control of energy homeostasis: different circuits, different purposes. Physiol Behav 2001;74:683-701.

13. Palmiter RD, Erickson JC, Hollopeter G, Baraban SC, Schwartz MW. Life without neuropeptide Y. Recent Prog Horm Res 1998;53:163-199.

14. Crawley JN. The role of galanin in feeding behavior. Neuropeptides 1999;33:369-375.

15. Wang J, Akabayashi A, Yu HJ, Dourmashkin J, Alexander JT, Silva I, Lighter J, Leibowitz SF. Hypothalamic galanin: control by signals of fat metabolism. Brain Res 1998;804:7-20.

16. Jequier E. Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci 2002;967:379-388.

17. Wilding JP. Neuropeptides and appetite control. Diabetes Med 2002;19:619-627.

18. Schwartz MW, Figlewicz DP, Woods SC, Porte D Jr, Baskin DG. Insulin, neuropeptide Y, and food intake. Ann N Y Acad Sci 1993;692:60-71.

19. Wang J, Leibowitz KL. Central insulin inhibits hypothalamic galanin and neuropeptide Y gene expression and peptide release in intact rats. Brain Res 1997;777:231-236.

20. Tempel DL, Leibowitz KJ, Leibowitz SF. Effects of PVN galanin on macronutrient selection. Peptides 1988;9:309-314.

21. Leibowitz SF, Kim T. Impact of a galanin antagonist on exogenous galanin and natural patterns of fat ingestion. Brain Res 1992;599:148-152.

22. Akabayashi A, Koenig JI, Watanabe Y, Alexander JT, Leibowitz SF. Galanin-containing neurons in the paraventricular nucleus: a neurochemical marker for fat ingestion and body weight gain. Proc Natl Acad Sci U S A 1994;91:10375-10379.

23. Leibowitz SF, Akabayashi A, Wang J. Obesity on a high-fat diet: role of hypothalamic galanin in neurons of the anterior paraventricular nucleus projecting to the median eminence. J Neurosci 1998;18:2709-2719.

24. Corwin RL, Rowe PM, Crawley JN. Galanin and the galanin antagonist M40 do not change fat intake in a fat-chow choice paradigm in rats. Am J Physiol 1995;269:R511-R518.

25. Smith BK, York DA, Bray GA. Effects of dietary preference and galanin administration in the paraventricular or amygdaloid nucleus on diet self-selection. Brain Res Bull 1996;39:149-154.

26. Beck B, Stricker-Krongrad A, Burlet A, Cumin F, Burlet C. Plasma leptin and hypothalamic neuropep-tide Y and galanin levels in Long-Evans rats with marked dietary preferences. Nutr Neurosci 2001;4:39-50.

27. Stanley BG, Daniel DR, Chin AS, Leibowitz SF. Paraventricular nucleus injections of peptide YY and neuropeptide Y preferentially enhance carbohydrate ingestion. Peptides 1985;6:1205-1211.

28. Giraudo SQ, Kotz CM, Grace MK, Levine AS, Billington CJ. Rat hypothalamic NPY mRNA and brown fat uncoupling protein mRNA after high-carbohydrate or high-fat diets. Am J Physiol 1998;266:R1578-R1583.

29. Ziotopoulou M, Mantzoros CS, Hileman SM, Flier JS. Differential expression of hypothalamic neu-ropeptides in the early phase of diet-induced obesity in mice. Am J Physiol Endocrinol Metab 2000;279:E838-E845.

30. Shimokawa T, Kumar MV, Lane MD. Effect of a fatty acid synthase inhibitor on food intake and expression of hypothalamic neuropeptides. Proc Natl Acad Sci U S A 2002; 99:66-71.

31. Vezzani A, Sperk G, Colmers WF. Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci 1999;22:25-30.

32. Baraban SC. Neuropeptide Y and limbic seizures. Rev Neurosci 1998;9:117-128.

33. Erickson JC, Clegg KE, Palmiter RD. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 1996;381:415-421.

34. Baraban SC, Hollopeter G, Erickson JC, Schwartzkroin PA, Palmiter RD. Knock out mice reveal a critical antiepileptic role for neuropeptide Y. J Neurosci 1997;17:8927-8936.

35. DePrato Primeaux S, Holmes PV, Martin RJ, Dean RG, Edwards GL. Experimentally induced attenuation of neuropeptide-Y gene expression in transgenic mice increases mortality rate following seizures. Neurosci Lett 2000;287:61-64.

36. Marsh DJ, Baraban SC, Hollopeter G, Palmiter RD. Role of the Y5 neuropeptide Y receptor in limbic seizures. Proc Natl Acad Sci U S A 1999;96:13518-13523.

37a. Vezzani A, Michalkiewicz M, Michalkiewicz T, et al. Seizure susceptibility and epileptogenesis are decreased in transgenic rats overexpressing neuropeptide Y. Neuroscience 2002;110:237-243.

37. Baraban SC. Antiepileptic actions of neuropeptide Y in the mouse hippocampus require Y5 receptors. Epilepsia 2002;43 (Suppl 5):S9-S13.

38. Mazarati AM, Hohmann JG, Bacon A, Liu H, Sankar R, Steiner RA, Wynick D, Wasterlain CG. Modulation of hippocampal excitability and seizures by galanin. J Neurosci 2000;20:6276-6281.

39. Mazarati AM, Liu H, Soomets U, Sankar R, Shin D, Katsumori H, Langel U, Wasterlain CG. Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus. J Neurosci 1998;18:10070-10077.

40. Saar K, Mazarati AM, Mahlapuu R, Hallnemo G, Soomets U, Kilk K, Hellberg S, Pooga M, Tolf BR, Shi TS, Hokfelt T, Wasterlain C, Bartfai T, Langel U. Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc Natl Acad Sci U S A 2002;99:7136-7141.

41. Kokaia M, Holmberg K, Nanobashvili A, Xu ZQ, Kokaia Z, Lendahl U, Hilke S, Theodorsson E, Kahl U, Bartfai T, Lindvall O, Hökfelt T. Suppressed kindling epileptogenesis in mice with ectopic overexpression of galanin. Proc Natl Acad Sci U S A 2001;98:14006-14011.

42. Jacoby AS, Hort YJ, Constantinescu G, Shine J, Iismaa TP. Critical role for GALR1 galanin receptor in galanin regulation of neuroendocrine function and seizure activity. Mol Brain Res 2002;107:195-200.

43. Vining EP, Pyzik P, McGrogan J, Hladky H, Anand A, Kriegler S, Freeman JM. Growth of children on the ketogenic diet. Dev Med Child Neurol 2002;44:796-802.

44. Fery F, Bourdoux P, Christophe J, Balasse EO. Hormonal and metabolic changes induced by an isocaloric isoproteinic ketogenic diet in healthy subjects. Diabetes Metab 1982;8:299-305.

45. Langfort J, Pilis W, Zarzeczny R, Nazar K, Kaciuba-Uscilko H. Effect of low-carbohydrate-ketogenic diet on metabolic and hormonal responses to graded exercise in men. J Physiol Pharmacol 1996;47:361-371.

46. Sankar R, Sotero de Menezes M. Metabolic and endocrine aspects of the ketogenic diet. Epilepsy Res 1999;37:191-201.

47. Fraser DA, Thoen J, Bondhus S, Haugen M, Reseland JE, Dj0seland 0, Forre 0, Kjeldsen-Kragh J. Reduction in serum leptin and IGF-1 but preserved T-lymphocyte numbers and activation after a keto-genic diet in rheumatoid arthritis patients. Clin Exp Rheumatol 2000;18:209-214.

48. Sharman MJ, Kraemer WJ, Love DM, Avery NG, Gomez AL, Scheett TP, Volek JS. A ketogenic diet favorably affects serum biomarkers for cardiovascular disease in normal-weight men. J Nutr 2002;132:1879-1885.

49. Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Safety 2001;24:969-978.

50. Harney JP, Madara J, Madara J, I'Anson H. Effects of acute inhibition of fatty acid oxidation on latency to seizure and concentrations of beta hydroxybutyrate in plasma of rats maintained on calorie restriction and/or the ketogenic diet. Epilepsy Res 2002;49:239-246.

51. Schachter SC. Neuroendocrine aspects of epilepsy. Neurol Clin 1994;12:31-40.

52. Bauer J. Interactions between hormones and epilepsy in female patients. Epilepsia 2001;42 (Suppl 3):S20-S22.

53. Xu ZQ, Shi TJ, Hokfelt T. Galanin/GMAP- and NPY-like immunoreactivities in locus coeruleus and noradrenergic nerve terminals in the hippocampal formation and cortex with notes on the galanin-R1 and -R2 receptors. J Comp Neurol 1998;392:227-251.

54. Hokfelt T, Xu ZQ, Shi TJ, Holmberg K, Zhang X. Galanin in ascending systems. Focus on coexistence with 5-hydroxytryptamine and noradrenaline. Ann N Y Acad Sci 1998;863:252-263.

55. Steiner RA, Hohmann JG, Holmes A, Wrenn CC, Cadd G, Jureus A, Clifton DK, Luo M, Gutshall M, Ma SY, Mufson EJ, Crawley JN. Galanin transgenic mice display cognitive and neurochemical deficits characteristic of Alzheimer's disease. Proc Natl Acad Sci U S A 2001;98:4184-4189.

56. Kohler C, Smialowska M, Eriksson LG, Chanpalay V, Davies S. Origin of the neuropeptide Y innervation of the rat retrohippocampal region. Neurosci Lett 1986;65:287-292.

57. Schon F, Allen JM, Yeats JC, Kent A, Kelly JS, Bloom SR. The effect of 6-hydroxydopamine, reser-pine and cold stress on the neuropeptide Y content of the rat central nervous system. Neuroscience 1986;19:1247-1250.

58. Wilcox BJ, Unnerstall JR. Identification of a subpopulation of neuropeptide Y-containing locus coeruleus neurons that project to the entorhinal cortex. Synapse 1990;6:284-291.

Diabetes 2

Diabetes 2

Diabetes is a disease that affects the way your body uses food. Normally, your body converts sugars, starches and other foods into a form of sugar called glucose. Your body uses glucose for fuel. The cells receive the glucose through the bloodstream. They then use insulin a hormone made by the pancreas to absorb the glucose, convert it into energy, and either use it or store it for later use. Learn more...

Get My Free Ebook


Post a comment